FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences:
Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA
Date: Monday, November 10, 2025
Live Webcast: 3:00 pm EST
Management to participate in one-on-one meetings throughout the conference
Stifel 2025 Healthcare Conference in New York, NY
Date: Wednesday, November 12, 2025
Live Webcast: 4:40 pm EST
Management to participate in one-on-one meetings throughout the conference
Jefferies Global Healthcare Conference in London, UK
Date: Tuesday, November 18, 2025
Live Webcast: 9:30 am EST / 2:30 pm GMT
Management to participate in one-on-one meetings throughout the conference
16th Annual Craig-Hallum Alpha Select Conference in New York, NY
Date: Tuesday, November 18, 2025
Management to participate in one-on-one meetings throughout the conference
8th Annual Evercore Healthcare Conference in Miami, FL
Date: Tuesday, December 2, 2025
Live Webcast: 3:25 pm EST
Management to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
| Last Trade: | US$17.56 |
| Daily Change: | -0.10 -0.57 |
| Daily Volume: | 266,825 |
| Market Cap: | US$1.250B |
November 04, 2025 October 30, 2025 October 23, 2025 August 07, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
